APOL1-mediated Proteinuric Kidney Disease
Title of Research Study: A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 12 Years and Older with APOL1-mediated Proteinuric Kidney Disease (Vertex)
| Enrollment Criteria
Male or female who is between 18 and 65 years (Phase 2) and 12 and 65 years (Phase 3). Phase 2 now recruiting. Has an APOL1 genotype of G1/G1, G2/G2, or G1/G2, and has Proteinuric kidney disease.
| Treatment: VX-147 v. Placebo
Sponsor: Vertex Pharmaceuticals
| Institution: University of Florida Nephrology PI: Dr. Wai Lang Lau Contact for Enrollment
Kathy McCray, BS, Clinical Research Coordinator II
kathy.mccray@medicine.ufl.edu | 352-294-5068 |
|
| FSGS - Focal Glomerulosclerosis | Title of Research Study
COMPLEXA FIRSTx CXA-10-204: A PHASE 2 MULTICENTER, OPEN LABEL, RANDOMIZED STUDY OF TWO TITRATION REGIMENS OF ORAL CXA-10 IN SUBJECTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
| | PI: Dr. Fornoni, Dr. Drexler, Dr.Contreras | | Sponsor: Complexa Inc. | | Drug: CXA-10 | Institution: UM Nephrology
Contact for Enrollment:
Jacqueline Vassallo, CCRP.
jvassall@med.miami.edu
Tel: 305-243-4691 |
| FSGS - Focal Glomerulosclerosis | Title of Research Study
DUPLEX 021FSGS16010: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
| | PI: Dr. Fornoni, Dr.Contreras, Dr. Drexler | | Sponsor: Retrophin Inc. | | Drug: Sparsentan | Institution: UM Nephrology
Contact for Enrollment:
Jacqueline Vassallo, CCRP.
jvassall@med.miami.edu
Tel: 305-243-4691 |
| FSGS - Focal Glomerulosclerosis | Title of Research Study
PFIZER C0221002: A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSIS IN ADULT SUBJECTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
| | PI: Dr. Fornoni, Dr. Contreras | | Sponsor: Pfizer | | Drug: PF-06730512 | Institution: UM Nephrology
Contact for Enrollment:
Jacqueline Vassallo, CCRP.
jvassall@med.miami.edu
Tel: 305-243-4691 |
FSGS, MN, MCD, IgA
| Title of Research Study: NEPTUNE: The Nephrotic Syndrome Study Network
| | PI: Dr. Fornoni, Dr.Contreras, Dr. Lenz | | Sponsor: NIH-Office of Rare Kidney Disease-NIDDK, DHHS-NephCure Kidney International, The University of Michigan | | Active/Enrolled/InScreening: 4/51/1 | Institution: UM Nephrology
Contact for Enrollment:
Jacqueline Vassallo, CCRP.
jvassall@med.miami.edu
Tel: 305-243-4691 |
FSGS, MCD, IgA, MN
| Title of Research Study: CureGN: Cure Glomerulonephropathy Network
| | PI: Dr. Fornoni, Dr.Contreras, Dr. Lenz | | Sponsor: NIH-NIDDK-NephCure Kidney International | | Active/Enrolled/InScreening: 7/10/0 | Institution: UM Nephrology
Contact for Enrollment:
Jacqueline Vassallo, CCRP.
jvassall@med.miami.edu
Tel: 305-243-4691 |
|
Florida Women in Nephrology Chair
FSN President
Print Page